New drug duo tested in fight against rare, aggressive blood cancer
NCT ID NCT07007052
Summary
This study is testing whether combining two drugs, tagraxofusp and venetoclax, is safe and effective for adults newly diagnosed with a rare and aggressive blood cancer called BPDCN. The main goal is to see if this combination leads to a complete remission after three months of treatment. Participants will receive at least three cycles of the drugs, and their response will determine if they continue treatment, receive a stem cell transplant, or stop therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMIENS - CH Amiens Picardie Site Sud
Amiens, 80054, France
-
ANGERS - CHU - Maladies du sang
Angers, 49933, France
-
AP-HP - Hôpital Necker
Paris, 75015, France
-
AP-HP- CRETEIL - CHU Henri Mondor
Créteil, 94000, France
-
APHP - HOPITAL COCHIN - Hématologie
Paris, 75014, France
-
APHP - Hôpital Saint-Louis - Hématologie adultes
Paris, 75010, France
-
ARGENTEUIL - Centre hospitalier Victor Dupouy
Argenteuil, France
-
AVIGNON - Centre Hospitalier
Avignon, 84000, France
-
BESANCON - Hôpital Jean Minjoz - Hématologie
Besançon, 25030, France
-
BORDEAUX - Hôpital Haut-Levêque
Pessac, 33600, France
-
CHU SAINT-ETIENNE - iCHUSE
Saint-Etienne, 42271, France
-
CLAMART - Hôpital d'Instruction des Armées de Percy
Clamart, 92140, France
-
Clermont-Ferrand - Chu Estaing
Clermont-Ferrand, 63000, France
-
Corbeil-Essonnes - Ch Sud Francilien
Corbeil-Essonnes, France
-
Grenoble CHU - Hématologie Clinique
Grenoble, 38043, France
-
LILLE CHU - Hôpital Claude Huriez
Lille, 59037, France
-
LYON HCL- Site Sud
Lyon, France
-
Limoges CHU
Limoges, France
-
MARSEILLE - Institut Paoli-Calmettes
Marseille, 13000, France
-
METZ - CHR Metz-Thionville
Metz, 57085, France
-
MULHOUSE GHRMSA - Hôpital E. Muller - Hématologie
Mulhouse, 68070, France
-
Montpellier - Chu Saint Eloi
Montpellier, France
-
NANCY - CHU de Brabois
Vandœuvre-lès-Nancy, 54500, France
-
NANTES - Hôpital Hôtel Dieu - Hématologie Clinique
Nantes, 44093, France
-
Nimes CHU
Nîmes, France
-
POITIERS - Hôpital La Milétrie - Hématologie Clinique
Poitiers, 86000, France
-
REIMS - Hôpital Robert Debré - Hématologie Clinique
Reims, 51100, France
-
RENNES - CHU Pontchaillou - Hématologie Clinique
Rennes, 35033, France
-
ROUEN - Centre Henri Becquerel - Service Hématologie Clinique
Rouen, 76038, France
-
Strasbourg - Institut de Cancerologie Strasbourg
Strasbourg, 67200, France
-
TOURS - Hôpital Bretonneau
Tours, 37000, France
-
Toulouse - IUCT Oncopole - Service d'Hématologie
Toulouse, France
-
VERSAILLES - Hôpital André Mignot
Versailles, France
-
Villejuif Igr - Gustave Roussy
Villejuif, 94804, France
Conditions
Explore the condition pages connected to this study.